Date Title Description PDF
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
31 Jan 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 24 January 2022 and 28 January 2022 Download
24 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 January 2022 and 21 January 2022 Download
17 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 10 January 2022 and 14 January 2022 Download
10 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 January 2022 and 7 January 2022 Download
03 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 27 December 2021 and 31 December 2021 Download

Pages

Date Title Description PDF
08 Oct 2018 Share capital increases and reductions Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase Download
05 Oct 2018 Buy-back programmes, stabilisation and treasury stock Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. Download
04 Oct 2018 Share capital increases and reductions Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights Download
04 Oct 2018 Liquidity contracts and specialists The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. Download
04 Oct 2018 Share capital increases and reductions Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights Download

Pages